Interpace Biosciences

Interpace Biosciences Current Assets

The Current Assets of Interpace Biosciences (IDXG) as of Oct 19, 2026 is 1.11 M USD. In the previous year, Current Assets was 9.78 M USD — a change of -88.61% (lower).

Current Assets

1.11 MUSD

YoY

-88.61%

Last updated:

Current Assets of Interpace Biosciences is 2025 1.11 M USD. Current Assets of Interpace Biosciences was 2024 9.78 M USD. It decreases by -88.61% lower compared to the previous year.

The Interpace Biosciences Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
17.74 M USD
Jan 1, 2019
18.30 M USD
Jan 1, 2020
16.15 M USD
Jan 1, 2021
11.40 M USD
Jan 1, 2022
6.90 M USD
Jan 1, 2023
6.33 M USD
Jan 1, 2024
9.78 M USD
Jan 1, 2025
1.11 M USD
The Interpace Biosciences Current Assets history
YEARCurrent AssetsYoY
1.11 MUSD-88.61%
9.78 MUSD+54.48%
6.33 MUSD-8.33%
6.90 MUSD-39.43%
11.40 MUSD-29.40%
16.15 MUSD-11.76%
18.30 MUSD+3.15%
17.74 MUSD-10.28%
19.77 MUSD+336.35%
4.53 MUSD-77.96%
20.56 MUSD-51.24%
42.16 MUSD-39.93%
70.19 MUSD-4.50%
73.50 MUSD-11.37%
82.93 MUSD+293.82%
21.06 MUSD-11.04%
23.67 MUSD-6.37%
25.28 MUSD-32.11%
37.24 MUSD-19.49%
46.25 MUSD-22.07%
59.35 MUSD+20.20%
49.38 MUSD-29.99%
70.53 MUSD-12.16%
80.29 MUSD-23.20%
104.55 MUSD-25.89%
141.07 MUSD+49.28%
94.50 MUSD+28.05%
73.80 MUSD+520.17%
11.90 MUSD+63.01%
7.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences Inc., headquartered in Parsippany, New Jersey, develops and sells diagnostic clinical and pharma services. The company offers five commercialized molecular tests and one in clinical evaluation, including PancraGEN for pancreatic cancer diagnosis, PanDNA for a limited factor snapshot, ThyGeNEXT for thyroid cancer evaluation, ThyraMIR v2 for thyroid cancer diagnosis, and RespriDX to differentiate lung cancer origins. With 94 employees, it operates in the Health Care sector, focusing on molecular diagnostics and bioinformatics solutions for cancer risk assessment. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

Current Assets of Interpace Biosciences is 1.11 M USD in 2025.

Current Assets of Interpace Biosciences changed from 9.78 M USD to 1.11 M USD, representing a -88.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Interpace Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Interpace Biosciences

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Interpace Biosciences